Status:
COMPLETED
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
Lead Sponsor:
Lineage Cell Therapeutics, Inc.
Conditions:
Cervical Spinal Cord Injury
Spine Injury
Eligibility:
All Genders
18-69 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively...
Eligibility Criteria
Inclusion
- Major
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI
- Major
Exclusion
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) \> 35 or weight \> 300 lbs.
- Active participation in another experimental procedure/intervention
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02302157
Start Date
March 1 2015
End Date
December 1 2018
Last Update
July 14 2021
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ. of California at San Diego
La Jolla, California, United States, 92093
2
Rancho Los Amigos/USC
Los Angeles, California, United States
3
Stanford University/Santa Clara Valley Medical Center
San Jose, California, United States, 95128
4
Shepherd Center
Atlanta, Georgia, United States, 30309